8-K: BriaPro Therapeutics Corp. Releases Unaudited Interim Financials Following Spin-Out From BriaCell

BriaPro Therapeutics Corp., a subsidiary of BriaCell, has released its unaudited interim financial statements for the three and six months ended January 31, 2024, following its spin-out transaction.

Summary

• BriaPro Therapeutics Corp., a two-thirds owned subsidiary of BriaCell Therapeutics Corp., released its unaudited condensed interim financial statements for the three and six months ended January 31, 2024.
• The company was incorporated on May 15, 2023, and the financials reflect the period after its spin-out from BriaCell on August 31, 2023.
• BriaPro is a pre-clinical immuno-oncology biotechnology company focused on developing Bria-TILsRx and PKC inhibitors.
• The company reported a net loss of $245,960 for the six-month period ended January 31, 2024, and a loss of $117,934 for the three-month period ended January 31, 2024.
• Research and development expenses were $168,563 for the six-month period and $104,103 for the three-month period.
• General and administrative expenses were $88,494 for the six-month period and $21,191 for the three-month period.
• The company's total assets were $207,432, with current assets of $1 and non-current assets of $207,431, primarily intangible assets.
• Total liabilities were $438,799, including $250,678 in current liabilities and $188,121 in non-current liabilities related to warrant liability.
• Shareholders' equity showed a deficit of $231,367.
• The company has 47,945,178 common shares issued and outstanding as of January 31, 2024.
• BriaCell beneficially owns or controls approximately 31,963,452 common shares, representing two-thirds of the issued and outstanding common shares.

Sentiment

Score: 4

Explanation: The document highlights the potential of BriaPro's technology and its strategic approach, but the financial situation is concerning with significant losses and a need for further capital. The company is in a very early stage of development and faces significant risks.

Positives

• BriaPro has a clear focus on developing novel immunotherapies using AI.
• The company has a pipeline of two lead drug discovery candidates: Bria-TILsRx and PKC inhibitors.
• BriaPro is leveraging AI technology to accelerate drug candidate selection.
• The company has a transition services agreement with BriaCell to support its operations.
• BriaPro has a team with expertise in multiple scientific areas relevant to drug discovery and development.
• The company has a licensing agreement for its PKC delta inhibitors.
• BriaPro is targeting a large market with its cancer therapeutics.

Negatives

• BriaPro has incurred significant losses since its incorporation, with a net loss of $245,960 for the six months ended January 31, 2024.
• The company has a negative working capital of $250,677 as of January 31, 2024.
• BriaPro is in the pre-clinical research stage and has not commenced commercial operations.
• The company is dependent on BriaCell for financing its operations.
• BriaPro is reliant on third-party suppliers and contract research organizations.
• The company faces competition from other research teams in the cancer therapeutics market.
• BriaPro has a limited operating history and no operating revenues.

Risks

• BriaPro shares are not currently listed on any stock exchange, and there is no assurance they will be in the future.
• The company may need to issue additional securities, which could dilute existing shareholders.
• BriaPro's clinical effectiveness and safety of its products are not yet supported by extensive clinical data.
• The company relies on third parties for manufacturing, development, and marketing.
• Pre-clinical and early clinical trial results may not be predictive of future results.
• BriaPro is highly dependent on key personnel, and their loss could adversely affect the company.
• The company may face intellectual property litigation.
• BriaPro may not be able to obtain adequate financing to continue operations.
• The company is subject to regulatory changes and government price controls.
• BriaPro is subject to data privacy and security regulations.
• The company faces product liability risks.
• BriaPro's intellectual property is under third-party licenses.
• The company is reliant on a transition services agreement with BriaCell.
• BriaCell, as a significant majority shareholder, can influence corporate actions.
• BriaPro's operations are subject to human error.
• The company may face difficulties in enforcing judgments against directors and officers residing outside of Canada.
• BriaPro may be subject to litigation.
• The company's insurance coverage may not be adequate.
• Social media may negatively impact the company's reputation.
• BriaPro may face competition from generic versions of its products.
• Patent terms may be inadequate to protect the company's competitive position.
• The company may face difficulties in enforcing its intellectual property rights.
• BriaPro's operations are subject to human error.
• The company may face difficulties in enforcing judgments against directors and officers residing outside of Canada.
• BriaPro may be subject to litigation.
• The company's insurance coverage may not be adequate.
• Social media may negatively impact the company's reputation.

Future Outlook

BriaPro expects to screen several multi-specific binding reagents and select at least one candidate to advance into IND enabling studies over the next year. Human clinical studies are expected to be initiated in the first half of 2025 for Bria-TILsRx and in the second half of 2025 for PKC inhibitors.

Management Comments

• Management asserts that BriaPro had not yet achieved commercial operations and was still in the Research stage at the time of the Arrangement.
• Management believes that the functional currency of the Company is the U.S. dollar.
• Management believes that the credit risk concentration with respect to financial instruments is remote.

Industry Context

This announcement reflects the ongoing trend of pharmaceutical companies spinning out assets to focus on core competencies and to allow for more specialized development of specific technologies. The use of AI in drug discovery is also a growing trend, and BriaPro is positioning itself to capitalize on this.

Comparison to Industry Standards

• BriaPro's financial results are typical for a pre-clinical stage biotechnology company, with significant research and development expenses and no revenue.
• The company's reliance on third-party contract research organizations is a common practice in the biotech industry to manage costs and access specialized expertise.
• The use of AI in drug discovery is becoming increasingly common, with companies like Recursion Pharmaceuticals and Exscientia leading the way in this field.
• BriaPro's focus on immuno-oncology aligns with a major trend in cancer therapeutics, with companies like Bristol Myers Squibb and Merck leading the market with checkpoint inhibitors.
• The development of multi-specific binding reagents like Bria-TILsRx is a novel approach, with companies like Amgen and Roche developing similar technologies.
• The development of PKC inhibitors is less common, but BriaPro's approach is differentiated by its use of AI to optimize drug-like characteristics.
• Compared to other early-stage biotech companies, BriaPro's financial position is weak, with a negative working capital and reliance on its parent company for funding.

Related Party Transactions

• As of January 31, 2024, the balance owing to BriaCell group companies is $196,549 comprising the fixed monthly services of $100,000 and direct expenses incurred by Briacell on behalf of BriaPro $96,549.
• During the six-month period ended January 31, 2024, the Company incurred Services and direct expense paid for by Briacell in the amount of $196,549.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises.
• Employees may be impacted by the company's financial instability.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors face the risk of non-payment due to the company's financial situation.

Next Steps

• BriaPro expects to screen several different multi specific binding reagents for activity in vitro as well as in mouse models of cancer.
• BriaPro also expects to select at least one candidate to advance into IND enabling studies.
• Human clinical studies are expected to be initiated in the first half of 2025 for Bria-TILsRx.
• Human clinical studies are expected to be initiated in the second half of 2025 for PKC inhibitors.
• BriaPro will continue to optimize the structure of its proprietary protein kinase C delta inhibitors and advance to the candidates election stage.

Key Dates

Keywords

BriaPro Therapeutics, BriaCell Therapeutics, Immunotherapy, Cancer, Bria-TILsRx, PKC inhibitors, AI, Biotechnology, Drug development, Clinical trials, Spin-out, Financial statements